Invention Grant
- Patent Title: Use of equol for treating androgen mediated diseases
-
Application No.: US14810117Application Date: 2015-07-27
-
Publication No.: US09408825B2Publication Date: 2016-08-09
- Inventor: Edwin Douglas Lephart , Trent D. Lund , Robert J. Handa
- Applicant: Edwin Douglas Lephart , Trent D. Lund , Robert J. Handa
- Applicant Address: US UT Provo US CO Fort Collins
- Assignee: BRIGHAM YOUNG UNIVERSITY,COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
- Current Assignee: BRIGHAM YOUNG UNIVERSITY,COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
- Current Assignee Address: US UT Provo US CO Fort Collins
- Agency: Brinks Gilson & Lione
- Main IPC: A61K31/352
- IPC: A61K31/352 ; A23L1/30 ; A61K31/35 ; A61K31/353

Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Public/Granted literature
- US20150342924A1 USE OF EQUOL FOR TREATING ANDROGEN MEDIATED DISEASES Public/Granted day:2015-12-03
Information query